MGMT: A Potential Drug Target for Cancer and Other Diseases (G4255)

Target Name: MGMT

NCBI ID: G4255

MGMT

MGMT: A Potential Drug Target for Cancer and Other Diseases

MGMT (O-6-Methylguanine-DNA methyltransferase) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. Methylation of the promoter region of MGMT has been shown to repress gene expression, which can lead to the development of cancer.

MGMT is a enzyme that plays a crucial role in the epigenetic regulation of gene expression. It is a DNA methyltransferase that adds a methyl group to the promoter region of a gene. This methylation process not only helps to protect the gene from being expressed, but it also plays a key role in the regulation of gene expression.

Studies have shown that MGMT is involved in the regulation of various gene expression patterns in the body. For example, MGMT has been shown to be involved in the regulation of cell proliferation and differentiation. It has also been shown to play a role in the regulation of cell survival and the response to stress.

One of the key features of MGMT is its ability to add methyl groups to specific promoter regions of a gene. This allows for the regulation of gene expression at a specific level. MGMT has been shown to add methyl groups to promoter regions of genes that are involved in cancer development, such as the androgen receptor (AR).

In addition to its role in cancer development, MGMT has also been shown to be involved in the regulation of normal cellular processes. For example, MGMT has been shown to play a role in the regulation of cell migration and the development of tissues. It has also been shown to be involved in the regulation of cell adhesion and the development of tissues.

The potential drug target or biomarker status of MGMT is due to its involvement in the regulation of various gene expression patterns in the body. MGMT has also been shown to play a role in the regulation of cancer development and has been identified as a potential drug target.

In conclusion, MGMT is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its role in the regulation of gene expression patterns in the body makes it an attractive target for drug development. Further research is needed to fully understand the potential of MGMT as a drug target or biomarker.

Protein Name: O-6-methylguanine-DNA Methyltransferase

Functions: Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated

The "MGMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MGMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets